Yifat S. Oren

Head of Discovery and Research
Splisense Ltd. Jerusalem, Israel, Israel

Poster(s):

• (615) Antisense Oligonucleotide-Based Drug Development for Cystic Fibrosis Patients Carrying the 2789+5 G-to-A Splicing Mutation
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (618) SPL84-23-1 Antisense Oligonucleotide Modulating the 3849+10kb C-T Splicing Defect, Has an Additive Effect with TRIKAFTA in Primary HBE Cells from 3849 Patients
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (619) Antisense Oligonucleotide Splicing Modulation as a Novel Cystic Fibrosis Therapeutic Approach for the W1282X Nonsense Mutation
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (620) Antisense Oligonucleotide Splicing Modulation as a Novel Cystic Fibrosis Therapeutic Approach for the N1303K Nonsense Mutation
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET